Vor Biopharma has seen a sharp swing in fortunes over the past few years, and the stock’s long slide now sits against a much stronger year to date. With that backdrop, the key issue for investors is whether the current share price is in line with what Vor Biopharma’s earnings can reasonably support. The share price has fallen 94.4% over the past 5 years, which puts a lot of weight on the question of whether today’s valuation still lines up with the business’s earnings power. Recent updates...
In September 2026, Vor Biopharma reported a post hoc analysis from a China-based Phase 3 trial showing that telitacicept produced deep, durable clinical responses and was generally well tolerated over 48 weeks in adults with generalized myasthenia gravis. The analysis highlighted that most patients who reached minimal symptom expression maintained it and spent much of their remaining follow-up in this state, underscoring the therapy’s potential to meaningfully reduce daily symptom burden in...
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust liquidity position. Read why VOR stock is a buy.
Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.
Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the comple
Vor Biopharma (VOR) completed enrollment in Upstream MG, a global phase 3 registrational trial evalu
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The
Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET Citi’s 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9
This is the newest page. Registered accounts read further back.